Skip to main navigation Skip to search Skip to main content

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

  • KESTREL Investigators
  • Attikon University Hospital
  • Universite Claude Bernard Lyon 1
  • Institute of Cancer Research
  • University of Texas MD Anderson Cancer Center
  • Sungkyunkwan University
  • Japanese Foundation for Cancer Research
  • University of North Carolina at Chapel Hill
  • Université catholique de Louvain
  • Memorial Sloan-Kettering Cancer Center
  • St. Petersburg State University
  • Leningrad Regional Oncology Dispensary
  • Omsk Regional Oncology Dispensary
  • China Medical University Taichung
  • Healthcare Global Enterprises Limited
  • Hospital Clínico San Carlos de Madrid
  • Sumy State University
  • Dana-Farber Cancer Institute
  • University of Duisburg-Essen
  • University of Tübingen
  • AstraZeneca
  • Johns Hopkins University

Research output: Contribution to journal › Article › peer-review

115   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology